Researchers identify key driver mutations in glioma samples that confirm tumor hetero

[News]

Caris Life Sciences today announced the presentation of data from a study in which researchers identified biomarker changes, including key driver mutations, in 89% of metachronous paired glioma tumors, indicating changes in response to therapy as the disease progresses.

More... (http://www.news-medical.net/news/20150601/Researchers-identify-key-driver-mutations-in-glioma-samples-that-confirm-tumor-heterogeneity.aspx)